RXRX vs. SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, and ASND
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Recursion Pharmaceuticals vs.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Summit Therapeutics received 273 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 58.38% of users gave Summit Therapeutics an outperform vote while only 57.69% of users gave Recursion Pharmaceuticals an outperform vote.
In the previous week, Recursion Pharmaceuticals had 17 more articles in the media than Summit Therapeutics. MarketBeat recorded 21 mentions for Recursion Pharmaceuticals and 4 mentions for Summit Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.44 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
Recursion Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Recursion Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Recursion Pharmaceuticals presently has a consensus price target of $8.75, indicating a potential downside of 11.66%. Summit Therapeutics has a consensus price target of $33.57, indicating a potential upside of 45.39%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Recursion Pharmaceuticals.
Summit Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Recursion Pharmaceuticals' return on equity of -76.56% beat Summit Therapeutics' return on equity.
Summary
Summit Therapeutics beats Recursion Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RXRX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free RXRX Stock Alerts